Please Wait
Applying Filters...
menu
    • menu
    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Istaroxime

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Windtree Files New Istaroxime Patent for Myocardial Arrhythmia
    Windtree Files New Istaroxime Patent for Myocardial Arrhythmia

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993691/0/en/Windtree-Announces-New-Istaroxime-Patent-Filing-for-Preventing-or-Reducing-the-Risk-of-Acute-Myocardial-Arrhythmia.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Windtree Partners for Potential Strategic Deal in Cardiogenic Shock
    Windtree Partners for Potential Strategic Deal in Cardiogenic Shock

    04 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/04/2991425/0/en/Windtree-Announces-Partnership-with-New-Growth-Advisors-to-Leverage-Positive-Phase-2-Istaroxime-Study-in-Cardiogenic-Shock-for-a-Potential-Strategic-Transaction.html

    GLOBENEWSWIRE
    04 Dec 2024
    Share Share
    Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock
    Windtree Therapeutic Initiates Seismic C Study in Cardiogenic Shock

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971647/0/en/Windtree-Therapeutics-Initiates-SEISMiC-C-Study-of-Istaroxime-in-SCAI-Stage-C-Cardiogenic-Shock-for-Planned-Completion-of-Phase-2b-and-Transition-to-Phase-3.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Windtree Announces Publication Of Istaroxime Phase 2b Design
    Windtree Announces Publication Of Istaroxime Phase 2b Design

    09 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//en/news-release/2024/10/09/2960460/0/en/Windtree-Announces-Publication-of-Positive-Istaroxime-Phase-2b-Study-Trial-Design.html

    GLOBENEWSWIRE
    09 Oct 2024
    Share Share
    Windtree Reports Ph 2b Results For Istaroxime In Heart Failure
    Windtree Reports Ph 2b Results For Istaroxime In Heart Failure

    30 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/09/30/2955170/0/en/Windtree-Announces-Positive-Phase-2b-Topline-Clinical-Results-with-Istaroxime-Significantly-Improving-Cardiac-Function-and-Blood-Pressure-in-Heart-Failure-Patients-in-Early-Cardiog.html

    GLOBENEWSWIRE
    30 Sep 2024
    Share Share
    Windtree’s shock med raises blood pressure in latest phase 2 win
    Windtree’s shock med raises blood pressure in latest phase 2 win

    26 Sep 2024

    // BIOSPACE

    https://www.biospace.com/press-releases/windtree-announces-positive-topline-results-from-its-phase-2b-seismic-extension-study-of-istaroxime-in-early-cardiogenic-shock

    BIOSPACE
    26 Sep 2024
    Share Share